Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 177

    1.

    Blood autoantibody and cytokine profiles predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis.

    Hueber W, Tomooka BH, Batliwalla F, Li W, Monach PA, Tibshirani RJ, Van Vollenhoven RF, Lampa J, Saito K, Tanaka Y, Genovese MC, Klareskog L, Gregersen PK, Robinson WH.

    Arthritis Res Ther. 2009;11(3):R76. Epub 2009 May 21.

    PMID:
    19460157
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    2.

    Effectiveness, predictive response factors, and safety of anti-tumor necrosis factor (TNF) therapies in anti-TNF-naive rheumatoid arthritis.

    Fernández-Nebro A, Irigoyen MV, Ureña I, Belmonte-López MA, Coret V, Jiménez-Núñez FG, Díaz-Cordovés G, López-Lasanta MA, Ponce A, Rodríguez-Pérez M, Calero E, González-Santos P.

    J Rheumatol. 2007 Dec;34(12):2334-42. Epub 2007 Nov 1.

    PMID:
    17985409
    [PubMed - indexed for MEDLINE]
    3.

    The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis.

    Chen HA, Lin KC, Chen CH, Liao HT, Wang HP, Chang HN, Tsai CY, Chou CT.

    Ann Rheum Dis. 2006 Jan;65(1):35-9. Epub 2005 Jun 23.

    PMID:
    15975966
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    4.

    Third generation anti-cyclic citrullinated peptide antibodies do not predict anti-TNF-alpha treatment response in rheumatoid arthritis.

    Dejaco C, Duftner C, Klotz W, Schirmer M, Herold M.

    Rheumatol Int. 2010 Feb;30(4):451-4. Epub 2009 Jun 9.

    PMID:
    19506882
    [PubMed - indexed for MEDLINE]
    5.

    Protein biochip array technology for cytokine profiling predicts etanercept responsiveness in rheumatoid arthritis.

    Fabre S, Dupuy AM, Dossat N, Guisset C, Cohen JD, Cristol JP, Daures JP, Jorgensen C.

    Clin Exp Immunol. 2008 Aug;153(2):188-95. Epub 2008 Jun 18.

    PMID:
    18549443
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    7.

    [Correlation between different clinical activity and anti CC-P (anti-cyclic citrullinated peptide antibodies) titres in rheumatoid arthritis treated with three different tumor necrosis factors TNF-alpha blockers].

    Benucci M, Turchini S, Parrochi P, Boccaccini P, Manetti R, Cammelli E, Manfredi M.

    Recenti Prog Med. 2006 Mar;97(3):134-9. Italian.

    PMID:
    16700418
    [PubMed - indexed for MEDLINE]
    8.

    CD11c as a transcriptional biomarker to predict response to anti-TNF monotherapy with adalimumab in patients with rheumatoid arthritis.

    Stuhlmüller B, Häupl T, Hernandez MM, Grützkau A, Kuban RJ, Tandon N, Voss JW, Salfeld J, Kinne RW, Burmester GR.

    Clin Pharmacol Ther. 2010 Mar;87(3):311-21. Epub 2009 Dec 23.

    PMID:
    20032971
    [PubMed - indexed for MEDLINE]
    9.

    Anti-TNFalpha therapy in rheumatoid arthritis and autoimmunity.

    Caramaschi P, Biasi D, Colombatti M, Pieropan S, Martinelli N, Carletto A, Volpe A, Pacor LM, Bambara LM.

    Rheumatol Int. 2006 Jan;26(3):209-14. Epub 2004 Dec 31.

    PMID:
    15627197
    [PubMed - indexed for MEDLINE]
    10.

    Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study.

    Mancarella L, Bobbio-Pallavicini F, Ceccarelli F, Falappone PC, Ferrante A, Malesci D, Massara A, Nacci F, Secchi ME, Manganelli S, Salaffi F, Bambara ML, Bombardieri S, Cutolo M, Ferri C, Galeazzi M, Gerli R, Giacomelli R, Grassi W, Lapadula G, Cerinic MM, Montecucco C, Trotta F, Triolo G, Valentini G, Valesini G, Ferraccioli GF; GISEA group.

    J Rheumatol. 2007 Aug;34(8):1670-3. Epub 2007 Jul 1. Erratum in: J Rheumatol. 2007 Sep;34(9):1947.

    PMID:
    17611987
    [PubMed - indexed for MEDLINE]
    11.

    B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents.

    Finckh A, Ciurea A, Brulhart L, Kyburz D, Möller B, Dehler S, Revaz S, Dudler J, Gabay C; Physicians of the Swiss Clinical Quality Management Program for Rheumatoid Arthritis.

    Arthritis Rheum. 2007 May;56(5):1417-23.

    PMID:
    17469098
    [PubMed - indexed for MEDLINE]
    Free Article
    12.

    Anti-TNF-alpha treatment in rheumatoid arthritis with anti-Ro/SSA antibodies. Analysis of 17 cases among a cohort of 322 treated patients.

    Cavazzana I, Bobbio-Pallavicini F, Franceschini F, Bazzani C, Ceribelli A, Bravi E, Zingarelli S, Caporali R, Cattaneo R, Montecucco CM.

    Clin Exp Rheumatol. 2007 Sep-Oct;25(5):676-83.

    PMID:
    18078613
    [PubMed - indexed for MEDLINE]
    13.

    Association of anti-CCP positivity and carriage of TNFRII susceptibility variant with anti-TNF-α response in rheumatoid arthritis.

    Vasilopoulos Y, Bagiatis V, Stamatopoulou D, Zisopoulos D, Alexiou I, Sarafidou T, Settas L, Sakkas L, Mamouris Z.

    Clin Exp Rheumatol. 2011 Jul-Aug;29(4):701-4. Epub 2011 Sep 1.

    PMID:
    21813066
    [PubMed - indexed for MEDLINE]
    14.

    Serum IgG antibodies to peptidylarginine deiminase 4 predict radiographic progression in patients with rheumatoid arthritis treated with tumour necrosis factor-alpha blocking agents.

    Halvorsen EH, Haavardsholm EA, Pollmann S, Boonen A, van der Heijde D, Kvien TK, Molberg Ø.

    Ann Rheum Dis. 2009 Feb;68(2):249-52. Epub 2008 Aug 22.

    PMID:
    18723564
    [PubMed - indexed for MEDLINE]
    15.

    High levels of interleukin 13 in rheumatoid arthritis sera are modulated by tumor necrosis factor antagonist therapy: association with dendritic cell growth activity.

    Tokayer A, Carsons SE, Chokshi B, Santiago-Schwarz F.

    J Rheumatol. 2002 Mar;29(3):454-61.

    PMID:
    11908556
    [PubMed - indexed for MEDLINE]
    16.

    The soluble tumor necrosis factor receptor etanercept: a new strategy for the treatment of autoimmune rheumatic disease.

    Cole P, Rabasseda X.

    Drugs Today (Barc). 2004 Apr;40(4):281-324. Review.

    PMID:
    15190385
    [PubMed - indexed for MEDLINE]
    17.

    Anti-nuclear antibodies, anti-DNA and C4 complement evolution in rheumatoid arthritis and ankylosing spondylitis treated with TNF-alpha blockers.

    Gonnet-Gracia C, Barnetche T, Richez C, Blanco P, Dehais J, Schaeverbeke T.

    Clin Exp Rheumatol. 2008 May-Jun;26(3):401-7.

    PMID:
    18578960
    [PubMed - indexed for MEDLINE]
    18.

    Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor alpha, tumor necrosis factor receptor superfamily member 9, and macrophage colony-stimulating factor.

    Rioja I, Hughes FJ, Sharp CH, Warnock LC, Montgomery DS, Akil M, Wilson AG, Binks MH, Dickson MC.

    Arthritis Rheum. 2008 Aug;58(8):2257-67.

    PMID:
    18668547
    [PubMed - indexed for MEDLINE]
    Free Article
    19.

    Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results.

    Braun-Moscovici Y, Markovits D, Rozin A, Toledano K, Nahir AM, Balbir-Gurman A.

    Isr Med Assoc J. 2008 Apr;10(4):277-81.

    PMID:
    18548981
    [PubMed - indexed for MEDLINE]
    Free Article
    20.

    Power Doppler ultrasonographic monitoring of response to anti-tumor necrosis factor therapy in patients with rheumatoid arthritis.

    Naredo E, Möller I, Cruz A, Carmona L, Garrido J.

    Arthritis Rheum. 2008 Aug;58(8):2248-56.

    PMID:
    18668537
    [PubMed - indexed for MEDLINE]
    Free Article

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Write to the Help Desk